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GSTM1 Tissue Genotype as a Recurrence Predictor in Non-
muscle Invasive Bladder Cancer
Tissue genotyping is more useful approach than using blood genomic DNA, which can 
reflect the effects of the somatic mutations in cancer. Although polymorphisms in 
glutathione S-transferase (GST) have been associated with the risk of bladder cancer (BC) 
development, few reports provide information about the prognosis of BC. We investigated 
glutathione S-transferase mu (GSTM1) and glutathione S-transferase theta (GSTT1) 
genotypes using genomic DNA from primary 165 BC tissue samples to assess the 
association with disease prognosis. DNA samples from tumor were analyzed by multiplex 
polymerase chain reaction (PCR). The results were compared with clinicopathological 
parameters. The prognostic significance of the GSTs was evaluated by Kaplan-Meier and 
multivariate Cox regression model. Kaplan-Meier estimates revealed significant differences 
in time to tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in non-
muscle invasive bladder cancer (NMIBC). Multivariate Cox regression analysis also revealed 
that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an 
independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1 
tissue genotype as a prognosticator for determining recurrence in NMIBC should prove 
highly useful in a clinical setting.
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
Bladder cancer (BC) involves a heterogeneous cell population, 
and numerous factors are likely to be involved in tumorigenesis 
(1). These factors result in uncontrolled growth of the cell popu-
lation, decreased cell death, invasion and metastasis, and may 
influence the patient’s prognosis. Identification of the aggres-
sive features of the cancer in patients with BC is very important 
for adequate management of this disease (2). While several mo-
lecular markers for the development, recurrence and progres-
sion of BC have been identified (3, 4), the limited value of these 
established prognostic markers has emphasized the need for 
novel molecular indicators of BC outcomes.
  Previous molecular epidemiologic studies have revealed that 
polymorphisms in glutathione S-transferase-mu (GSTM1) and 
glutathione S-transferase-theta (GSTT1) have been implicated 
as risk factors in BC (5, 6). Furthermore, a small number of re-
ports have added valuable information towards our understand-
ing of the clinicopathologic characteristics of BC (7, 8).
  Several environmental factors, as well as the activities of de-
toxification enzymes, have been associated with tumor devel-
opment in BC, and could also affect the clinical course of this 
disease. To date, there has been no published report describing 
the prognostic value of homozygous deletions of GSTM1 and 
GSTT1 in tumor tissues as markers of disease prognosis in pri-
mary BC patients with long-term follow-up. This study is the 
first and the only study that used tumor tissue to analyze the 
GSTM1 and GSTT1 genotypes to evaluate the prognosis of BC 
instead of blood genomic DNA. In the current study, we identi-
fied the GSTM1 tissue genotype as a prognosticator of recurrence 
in patients with primary non-muscle invasive bladder cancer 
(NMIBC). 
 
MATERIALS AND METHODS
Patients and tissue samples
We used primary BC tissue samples taken all from the initial 
primary tumor resection (no prior intravesical therapy or sys-
temic adjuvant chemotherapy) from 165 consecutive cases of 
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which were obtained from Chungbuk National University Hos-
pital between 1995 and 2007. To reduce confounding factors 
that may affect the analyses, any patients diagnosed with con-
comitant carcinoma in situ (CIS) lesion or CIS lesion alone were 
excluded. All tumors were macro-dissected, typically within 15 
min of surgical resection. Each BC specimen was confirmed by 
pathological analysis of a part of the tissue sample in fresh-fro-
zen sections from cystectomy and transurethral resection (TUR) 
specimens, and then frozen in liquid nitrogen and stored at -80°C 
until use. 
  Tumors were staged according to the 2002 TNM classifica-
tion (9) and the 1973 WHO grading system (10). In the case of 
NMIBC, TUR of the tumor was performed. A second TUR was 
performed 2-4 weeks after the initial resection when a BC spec-
imen did not include proper muscle or when a high-grade was 
detected (11). Patients who had multiple tumors, large tumors 
(≥ 3 cm in diameter), or high grade NMIBC received one cycle 
of intravesical treatment (Bacillus Calmette–Guérin [BCG] or 
mitomycin-C) (11, 12). Response to treatment was assessed by 
cystoscopy and urinary cytology. Patients who were free of dis-
ease within 3 months of commencement of treatment were as-
sessed every 3 months for the first 2 yr and every 6 months there-
after (11, 12). We defined recurrence as the relapse of primary 
NMIBC with a lower or equivalent pathologic stage, and pro-
gression as disease with a higher TNM stage when relapsed. In 
cases of muscle-invasive bladder cancer (MIBC), radical cys-
tectomy and complete pelvic lymph node dissection were per-
formed. Patients with pT3, pT4, or node-positive disease, based 
on the analysis of radical cystectomy specimens, received at 
least four cycles of cisplatin-based chemotherapy. Either clini-
cally metastatic disease, or non-cystectomy cases were exclud-
ed in this study. Each patient has been followed and managed 
according to the standard recommendation (13). Among MIBC 
cases, we defined progression as local regional recurrence or 
metastasis after radical cystectomy and adequate adjuvant che-
motherapy.
DNA extraction and multiplex PCR
Genomic DNA was isolated from frozen tumor tissue specimens 
using the Wizard Genomic DNA Purification System Kit (Pro-
mega, Maddison, WI, USA) in accordance with the manufac-
turer’s instructions. A multiplex PCR method was used to detect 
the presence or absence of the GSTM1 and GSTT1 polymor-
phisms in genomic DNA samples, as described previously (14). 
The primers used in the PCR were: 1) GSTM1 (219 bp) sense (5´-
GAA CTC CCT GAA AAG CTA AAG C-3´) and anti-sense (5´-GTT 
GGG CTC AAA TAT ACG GTG G-3´); 2) GSTT1 (372 bp) sense 
(5´-TTA GCT GAC CTC GTA GCC AT-3´) and anti-sense (5´-GAA 
GTC CTT GGC CTT CAG AA-3´); and 3) β-globin (268 bp) sense 
(5´-GAA GAG CCA AGG ACA GGT AC-3´) and anti-sense (5´-CAA 
CTT CAT CCA CGT TCA CC-3´). DNA (200 ng) was amplified in 
a total volume of 20 μL, containing 10 pM of each primer, 0.5 unit 
of Taq polymerase, 2.5 mM dNTP, and 10 × PCR buffer. Follow-
ing an initial denaturation step at 94°C for 5 min, 40 cycles of am-
plification were performed at: 1) 94°C for 60 sec; 2) 63°C for 60 
sec; and 3) 72°C for 60 sec. A final extension step was then per-
formed at 72°C for 10 min. Confirmation of PCR reactions was 
performed by electrophoresis of the amplified products on a 2% 
agarose gel. Positive and negative control samples were analyzed 
in each experiment. GSTM1 and GSTT1 genotypes were only 
scored in the presence of the internal reference gene (β-globin) 
product.
Statistical analysis
The chi-square test and Fisher’s exact test were used to analyze 
the frequencies of the genotypes according to clinicopathologi-
cal parameters. The Kaplan-Meier method was used to esti-
mate time to recurrence and progression, and differences were 
assessed using log-rank statistics. The prognostic value of the 
GSTM1 and GSTT1 genotypes for recurrence and progression 
of BC was analyzed with multivariate Cox proportional hazard 
regression models. Statistical analysis was performed using SPSS 
12.0 software (SPSS Inc., Chicago, IL, USA), and a P value of 
< 0.05 was considered statistically significant.
Ethics statement
The collection and analysis of all samples was approved by the 
institutional review board of Chungbuk National University (IRB 
approved number 2006-01-001), and informed consent was 
obtained from each subject.
RESULTS
Baseline characteristics
Table 1 lists the baseline characteristics of the 165 patients en-
rolled in this study. The median follow-up period of the primary 
Table 1. Baseline characteristics
Variables No. of patients (%)
Mean age ± SD (yr) 65.2 ± 12.0
Gender
   Male
   Female
135 (81.8)
  30 (18.2)
Grade
   G1
   G2
   G3
 
  29 (17.6)
  77 (46.7)
  59 (35.8)
Stage
   TaN0M0
   T1N0M0
   T2N0M0
   T3N0M0
   T4/Any T N+/M+
 
  24 (14.5)
  78 (47.3)
  25 (15.2)
14 (8.5)
  24 (14.5)
Median follow-up period (months) 57.3
SD, standard deviation.Ha Y-S, et al.  •  GSTM1 Tissue Genotype in Recurrence of Non-muscle Invasive Bladder Cancer
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BC patients was 57.3 months (range, 1.0-161.4). Total 20 of 102 
patients (19.6%) received the repeat TUR for the adequate tu-
mor staging. Intravesical therapy was performed in 50 patients 
(49.0%) after primary TUR including 39 patients treated with 
BCG, and 11 with mitomycin-C. In our study, patients who com-
pleted 6 times of intravesical therapy were counted in number. 
Fig. 1 shows 2% agarose gel demonstrating multiplex PCR ge-
notyping of genomic DNA samples for the detection of GSTM1 
and GSTT1 gene deletion. The frequencies of the GSTM1-null 
and GSTT1-null types were 69.1% and 47.9%, respectively.
Relationship between GSTM1 and GSTT1 genotype, and 
clinicopathological parameters
Table 2 summarizes the correlations between genotype and 
clinicopathological parameters in patients with NMIBC. The 
GSTM1-null genotype was observed in 30 of 36 NMIBCs (83.3%) 
with recurrence and in 41 of 66 (62.1%) without recurrence, 
which represented a statistically significant difference (P = 0.026). 
No significant correlations were observed between GSTM1 gen-
otype and the other clinicopathological parameters such as tu-
mor stage, grade, tumor size, multiplicity and progression. The 
GSTT1-positive genotype was more frequently detected in large-
sized (≥ 3 cm) than in small-sized NMIBC (< 3 cm) (28 of 46 or 
60.9% vs 21 of 56 or 37.5%, P = 0.019). The other parameters were 
not significantly associated with GSTT1 genotype. Associations 
between the genotype of GSTM1 or GSTT1 and clinicopatho-
logical features of MIBC were not found (Table 3).
Association between genotype of GSTM1 with recurrence 
of NMIBC
Kaplan-Meier estimates revealed a significant difference in time 
to tumor recurrence according to the GSTM1 genotype (log-rank 
test, P = 0.038, Fig. 2). However, recurrence-free survival was 
not related to the GSTT1 genotype. Multivariate Cox regression 
analysis revealed that the GSTM1 genotype was an independent 
predictor of bladder tumor recurrence (hazard ratio, 0.377; 95% 
372 bp
  M  1  2  3  4
268 bp
219 bp
Fig. 1. Electrophoretic findings of GSTM1 and GSTT1, Lane M: molecular size marker 
(100 bp DNA ladder); Lane 1: GSTM1-null/GSTT1-null type; Lane 2: GSTM1-null/
GSTT1-positive type; Lane 3: GSTM1-positive/GSTT1-null type; Lane 4: GSTM1-posi-
tive/GSTT1-positive type.
Table 2. Relationship between GSTM1 and GSTT1 genotypes, and clinicopathological 
parameters in non-muscle-invasive bladder cancer
Variables
GSTM1 GSTT1
Positive 
(%)
Null  
(%)
P 
Positive 
(%)
Null  
(%)
P 
Stage
   Ta
   T1
 
   9 (37.5)
 22 (28.2)
 
15 (62.5)
56 (71.8)
0.387*  
15 (62.5)
34 (43.6)
 
  9 (37.5)
44 (56.4)
0.105*
Grade 
   G1
   G2
   G3
 
   9 (31.0)
 19 (33.3)
   3 (30.0)
 
20 (69.0)
38 (66.7)
13 (70.0)
0.532*  
16 (55.2)
25 (43.9)
  8 (50.0)
 
13 (44.8)
32 (56.1)
  8 (50.0)
0.602*
Size
   < 3 cm
   ≥ 3 cm
 
 16 (28.6)
 15 (32.6)
 
40 (71.4)
31 (67.4)
0.659*  
21 (37.5)
28 (60.9)
 
35 (62.5)
18 (39.1)
0.019*
Number
   Single
   Multiple
 
 18 (29.5)
 13 (31.7)
 
43 (70.5)
28 (68.3)
0.813*  
30 (49.2)
19 (46.3)
 
31 (50.8)
22 (53.7)
0.778*
Recurrence
   No
   Yes
 
 25 (37.9)
   6 (16.7)
 
41 (62.1)
30 (83.3)
0.026*  
29 (43.9)
20 (55.6)
 
37 (56.1)
16 (44.4)
0.262*
Progression
   No
   Yes
 
 29 (32.2)
   2 (16.7)
 
61 (67.8)
10 (83.3)
0.337
†  
42 (46.7)
  7 (58.3)
 
48 (53.3)
  5 (41.7)
0.447*
*Chi-Square test; 
†Fisher’s Exact Test. GSTM1, Glutathione S-transferase-mu 1; GSTT1, 
Glutathione S-transferase-theta 1.
Table 3. Relationship between GSTM1 and GSTT1 genotypes, and clinicopathological 
parameters in muscle invasive bladder cancer
Variables
GSTM1 GSTT1
Positive 
(%)
Null  
(%)
P 
Positive 
(%)
Null  
(%)
P 
Stage
   T2N0M0
   T3N0M0
   T4/Any T  
      N+/M+
 
  9 (36.0)
  2 (28.2)
  9 (37.5)
 
16 (64.0)
12 (71.8)
15 (62.5)
0.923*  
16 (62.5)
10 (43.6)
11 (45.8)
 
  9 (37.5)
  4 (56.4)
13 (54.2)
0.204*
Grade
   G2
   G3
 
  6 (30.0)
  4 (32.6)
 
14 (70.0)
29 (67.4)
0.839*  
10 (50.0)
27 (62.8)
 
10 (50.0)
16 (37.2)
0.337*
Progression
   No
   Yes
 
13 (31.7)
  7 (31.8)
 
28 (68.3)
15 (68.2)
0.993*  
25 (61.0)
12 (54.5)
 
16 (39.0)
10 (45.5)
0.621*
*Chi-Square test. GSTM1, Glutathione S-transferase mu 1; GSTT1, Glutathione S- 
transferase theta 1.
Fig. 2. Kaplan-Meier estimate curves predict the probability of recurrence according 
to the GSTM1 genotype in patients with non-muscle invasive bladder cancer.
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confidence interval, 0.156-0.914; P = 0.031, Table 4).
DISCUSSION
The activities of specific enzymes can change with genotype. 
GSTM1 and GSTT1 are involved in cellular metabolism and 
detoxification of carcinogenic products, and these detoxifica-
tion related-enzymes are associated with tumorigenesis of BC 
(5, 6, 15, 16). Specific enzymes that are known to be important 
in carcinogenesis can also play a critical role in disease recur-
rence and progression after initial treatment.
  In this study, we investigated the GSTM1 and GSTT1 geno-
types in human primary BC tissues. The results demonstrated 
that the GSTM1 tissue genotype was a strong indicator for pre-
dicting recurrence in patients with primary NMIBC. However, 
the GSTM1 genotype was not associated with tumor progres-
sion. Previous blood genotype studies revealed that individuals 
with the GSTM1-null genotype were at great risk of developing 
BC (5, 6, 16). These results imply that the GSTM1-null genotype 
may contribute to the initiation of tumorigenesis in BC simply 
by promoting cell proliferation, rather than by the generation of 
certain aspects of the aggressive phenotype such as progression 
and invasion. There have been several studies aimed at identi-
fying the biologic potential of bladder tumors, which may help 
to better predict the clinical outcome of BC, including recurrence 
and progression (17-20). Since the molecular genetic aspects 
are different between recurrence and progression in NMIBC 
(21-23), it seems necessary to discriminate these two pathogen-
eses. Grossman et al. reported that p53 and retinoblastoma (RB) 
expression in T1 NMIBC can be used to predict progression only, 
and not recurrence without progression (19). Kim et al. (20) 
suggested that RUNX3 methylation was correlated with disease 
progression but did not detect a statistically significant associa-
tion between RUNX3 methylation and recurrence in NMIBC. A 
small number of reports have described tumor markers related 
to recurrence without progression in NMIBC (17, 18), however, 
cell cycle markers were reported to provide no added prognos-
tic information on tumor recurrence in NMIBC (17).  Van Rhijn 
et al. (18) suggested that FGFR3 mutation was a strong indica-
tor for predicting recurrence in NMIBC. However, the design of 
that study carried limitations in terms of a relatively small sam-
ple size and in including both primary and recurrence cases. In 
the present study, we used only 165 primary BC tissues with 
long-term follow-up. In our data, the conventional prognostic 
factors such as multiplicity, tumor size, stage and grade did not 
related to the recurrence in NMIBC on multivariate analysis. 
Although we do not know the exact reason, one possibility is 
that the patients at high risk of recurrence or progression un-
derwent second TUR or intravesical therapy, and these adju-
vant treatments might act as the confounding effects against 
the conventional prognostic factors.
  Most of the single nucleotide polymorphism (SNP) studies of 
GSTM1 and GSTT1 have been case control studies, or cross-sec-
tional studies based on epidemiology. There are several distinc-
tive aspects of the current study compared with previous SNP 
studies. First, we used genomic DNA from 165 primary BC tissue 
samples for the analysis. To date, there has been no study using 
tumor tissues to identify the genotype of GSTM1 and GSTT1. 
DNA from tumor tissues represents the effects of the somatic 
mutations, alterations occurring in tumor DNA could affect the 
gene expression. We have the expression analysis data for GSTM1 
and GSTT1 using tumor DNA. The mRNA expression of GSTM1 
and GSTT1 was higher in BC tissues with positive genotypes 
than in those with null genotypes (24). It also revealed that tu-
mor genotype might affect the expression of the specific gene. 
In these regards, we suggest that using genomic DNA from tu-
mor tissues to the genotypes of GSTM1 and GSTT1 is a more 
important and useful approach than using genomic DNA from 
blood which could also be affected by changes in the patient’s 
health status originating from other diseases unrelated to the 
cancer that investigators are attempting to analyze. Second, we 
performed definitive subgroup analysis and survival analyses 
such as Kaplan-Meier and Cox regression analysis with long-
term follow-up. Only a small number of studies have reported 
GSTM1 and GSTT1 genotype according to the stage and grade 
of the BC (7, 8, 25), and the results were inconsistent among the 
different ethnic groups. We analyzed all the factors affecting BC 
prognosis, including stage, grade, multiplicity and size, in con-
junction with GSTM1 and GSTT1 tissue genotypes. We found 
that the GSTT1-positive genotype was more frequently detected 
in large-sized (≥ 3 cm) than in small-sized NMIBC (< 3 cm). This 
finding supports our previous data showing that a GSTT1-null 
genotype is not a risk factor, but a protective factor, for BC (15). 
The GSTT1-positive genotype may reflect the aggressiveness of 
NMIBC, but further investigation to confirm this proposal will 
be needed.
  Frequent recurrence and progression are devastating events 
for both urologists and BC patients. The high incidence of recur-
rence results in considerable costs that make NMIBC one of the 
most expensive diseases to treat (26). Progression from NMIBC 
Table 4. Multivariate Cox regression analysis for prediction of recurrence in non-muscle 
invasive bladder cancer
Variables HR (95% CI) P
Age 0.991 (0.965-1.017) 0.476
Sex (male vs female) 1.099 (0.449-2.686) 0.836
Stage (Ta vs T1) 1.190 (0.481-2.949) 0.707
Grade (G1 and G2 vs G3) 0.851 (0.313-2.311) 0.751
Number (single vs multiple) 1.458 (0.693-3.069) 0.320
Size (< 3 cm vs ≥ 3 cm) 1.438 (0.734-2.815) 0.289
Intravesical therapy (No vs Yes) 1.384 (0.647-2.960) 0.403
GSTM1 (null vs positive) 0.377 (0.156-0.914) 0.031
HR, hazards ratio; CI, confidence interval; GSTM1, Glutathione S-transferase mu 1.Ha Y-S, et al.  •  GSTM1 Tissue Genotype in Recurrence of Non-muscle Invasive Bladder Cancer
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to MIBC or metastasis is not unusual and is often life-threaten-
ing to the patient. Efforts towards preventing these events are 
ongoing. The traditional methods include a second TUR, intra-
vesical drug instillation treatment, and early cystectomy (27, 28). 
Some reports have revealed that early cystectomy results in a 
superior 5-yr survival rate in comparison with bladder-sparing 
surgery (2). Cystectomy may lead to severe complications or 
morbidity (29), and there has been much controversy as to wheth-
er cystectomy represents over-treatment (30). If patients with 
NMIBC are likely to suffer from recurrence of the disease, but 
will never experience progression, the need for early cystecto-
my is diminished. Therefore, the usefulness of GSTM1 tissue 
genotype as a recurrence prognosticator demonstrated in the 
current study must be emphasized to urologists. However, in-
troducing this prognostic test for NMIBC into routine clinical 
practice requires further external validation in a prospective 
manner using a large number of samples.
  In conclusion, we showed that the GSTM1 tissue genotype 
has a predictive value for determining recurrence in NMIBC. It 
is suggested that the GSTM1 tissue genotype may play an im-
portant role in the prognosis of NMIBC in the clinical setting in 
the future.
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Tissue genotyping is more useful approach than using blood genomic DNA, which can reflect the effects of the somatic mutations 
in cancer. We investigated the genotype of GSTM1 and GSTT1 in bladder cancer (BC) using genomic DNA from 165 BC tissue 
samples, to assess the association with disease prognosis in BC. Kaplan-Meier estimates revealed significant differences in time to 
tumor recurrence according to the GSTM1 tissue genotype (P = 0.038) in non-muscle invasive bladder cancer (NMIBC). 
Multivariate Cox regression analysis also revealed that the tissue GSTM1 genotype (hazards ratio [HR]: 0.377, P = 0.031) was an 
independent predictor of bladder tumor recurrence in NMIBC. This identification of GSTM1 tissue genotype as a prognosticator for 
determining recurrence in NMIBC might prove highly useful in a clinical setting.